Cyteir Therapeutics, Inc. financial data

Industry
Pharmaceutical Preparations
Location
P.O. Box 80084, Stoneham, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 6, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.53K % +11.8%
Debt-to-equity 4.4 % -20.9%
Return On Equity -24.9 % +13.9%
Return On Assets -23.8 % +12.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36M shares +1.65%
Common Stock, Shares, Outstanding 36.1M shares +2.06%
Entity Public Float 69.5M USD -85.6%
Common Stock, Value, Issued 35K USD 0%
Weighted Average Number of Shares Outstanding, Basic 36M shares +1.99%
Weighted Average Number of Shares Outstanding, Diluted 36M shares +1.99%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24.9M USD -29.8%
General and Administrative Expense 13.4M USD -8.09%
Operating Income (Loss) -38.3M USD +23.5%
Nonoperating Income (Expense) 5.04M USD +462%
Net Income (Loss) Attributable to Parent -33.2M USD +32.3%
Earnings Per Share, Basic -0.95 USD/shares +67.7%
Earnings Per Share, Diluted -0.95 USD/shares +67.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 129M USD -16%
Assets, Current 131M USD -17%
Property, Plant and Equipment, Net 105K USD -94.4%
Operating Lease, Right-of-Use Asset 2.07M USD
Other Assets, Noncurrent 261K USD -89.5%
Assets 131M USD -19%
Accounts Payable, Current 508K USD -69.5%
Liabilities, Current 5.97M USD +2.63%
Operating Lease, Liability, Noncurrent 1.56M USD
Other Liabilities, Noncurrent 9K USD -99.5%
Liabilities 5.98M USD -22%
Retained Earnings (Accumulated Deficit) -163M USD -25.7%
Stockholders' Equity Attributable to Parent 125M USD -18.8%
Liabilities and Equity 131M USD -19%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.2M USD +16.4%
Net Cash Provided by (Used in) Financing Activities 103K USD +442%
Net Cash Provided by (Used in) Investing Activities 150K USD
Common Stock, Shares Authorized 280M shares 0%
Common Stock, Shares, Issued 36.1M shares +1.84%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.91M USD +19.7%
Deferred Tax Assets, Valuation Allowance 40.9M USD +49.2%
Deferred Tax Assets, Gross 42.1M USD +48.9%
Operating Lease, Liability 16K USD -99.4%
Payments to Acquire Property, Plant, and Equipment 191K USD +7.3%
Lessee, Operating Lease, Liability, to be Paid 100K USD -97%
Property, Plant and Equipment, Gross 503K USD -85.7%
Operating Lease, Liability, Current 16K USD -98.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 883K USD -3.29%
Lessee, Operating Lease, Liability, to be Paid, Year One 910K USD +1.22%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2K USD -99.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 833K USD -5.45%
Deferred Tax Assets, Operating Loss Carryforwards 27.2M USD +12.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40M shares 0%
Unrecognized Tax Benefits 856K USD +47.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Operating Lease, Payments 200K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 459K USD -37.6%
Deferred Tax Assets, Net of Valuation Allowance 1.21M USD +39.1%
Share-based Payment Arrangement, Expense 3.29M USD -33.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%